Tuberculosis Infectiousness and Host Susceptibility by Turner, RD et al.
The Journal of Infectious Diseases
S636 • JID 2017:216 (Suppl 6) • Turner et al
Tuberculosis Infectiousness and Host Susceptibility
Richard D. Turner,1 Christopher Chiu,2 Gavin J. Churchyard,3,4 Hanif Esmail,5,6 David M. Lewinsohn,7 Neel R. Gandhi,8 and Kevin P. Fennelly9
1Department of Respiratory Medicine, King’s College Hospital; 2Section of Infectious Diseases & Immunity, Imperial College London, United Kingdom; 3Aurum Institute and 4School 
of Public Health, University of Witwatersrand, Johannesburg, South Africa; 5Radcliffe Department of Medicine, University of Oxford, United Kingdom; 6Wellcome Center for 
Infectious Diseases Research in Africa, University of Cape Town, South Africa; 7Department of Molecular Microbiology and Immunology, Oregon Health & Science University, 
Portland; 8School of Medicine and Rollins School of Public Health, Emory University, Atlanta, Georgia; 9Pulmonary Clinical Medicine Section, Cardiovascular Pulmonary Branch, 
Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
The transmission of tuberculosis is complex. Necessary factors include a source case with respiratory disease that has developed suf-
ficiently for Mycobacterium tuberculosis to be present in the airways. Viable bacilli must then be released as an aerosol via the respi-
ratory tract of the source case. This is presumed to occur predominantly by coughing but may also happen by other means. Airborne 
bacilli must be capable of surviving in the external environment before inhalation into a new potential host—steps influenced by 
ambient conditions and crowding and by M. tuberculosis itself. Innate and adaptive host defenses will then influence whether new 
infection results; a process that is difficult to study owing to a paucity of animal models and an inability to measure infection directly. 
This review offers an overview of these steps and highlights the many gaps in knowledge that remain.
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The transmission of any infectious disease requires a source, a 
susceptible new potential host, and passage of the pathogen, by 
direct contact, by indirect contact (eg, by fomites or an environ-
mental medium, such as water), or via the air. Tuberculosis is 
the archetype of airborne-transmitted infectious diseases, with 
Mycobacterium tuberculosis serving as the causative agent [1]. For 
human tuberculosis, the source of the majority of new infections 
is other humans with pulmonary disease. Zoonotic tuberculosis, 
largely resulting from Mycobacterium bovis from cattle and their 
food products, is important in some contexts but accounts for 
only around 1.4% of cases of human tuberculosis overall [2].
Therefore, for the majority of cases, M. tuberculosis must 
exit the respiratory tract of the source case, survive the rigors 
of aerosolization and desiccation in the outside environment, 
be inhaled into the lung of the new potential host, and evade 
immune defenses to cause new infection (Figure 1). This over-
view presents what is known of these processes of tuberculosis 
transmission, and highlights where gaps in knowledge remain 
(Figure 2). 
INFECTIOUSNESS
Source Case
Tuberculosis has often been considered as distinct binary 
states of infection (asymptomatic, noninfectious with effective 
bacillary control) and disease (symptomatic, potentially infec-
tious with failure of bacillary control). However, this is probably 
an oversimplification, which may be hindering efforts for tuber-
culosis control [3, 4]. The pathology, presence of culturable 
bacilli, and symptoms do not appear simultaneously but likely 
develop over time, perhaps intermittently, with disease present 
prior to symptoms [5].
The development of an acquired cell-mediated immune 
response to M. tuberculosis 6–8 weeks following initial infection 
and dissemination facilitates the effective control of M. tuberculo-
sis within granulomata [6]. This is manifested by positive results 
of a tuberculin skin test (TST) or interferon γ–release assay 
(IGRA). The true extent of quiescence of this state of so-called 
latent infection is poorly understood. Similarly, little is known 
about the point of transition from this state to tuberculosis [4].
The process of failure to contain bacilli within granulomata 
has recently been demonstrated in a nonhuman primate model, 
resulting in pulmonary consolidation and bronchogenic spread 
of cellular infiltrate [7]. In human autopsy studies, a similar 
pneumonic infiltration has been observed as the first patholog-
ical sign of pulmonary disease. The initially small number of 
mycobacteria increases substantially as necrosis develops [8]. 
High-resolution imaging in clinical studies has also identified 
lung consolidation in some asymptomatic persons with a con-
ventional diagnosis of latent M. tuberculosis infection, correlat-
ing with a greater risk of symptomatic disease [5].
Development of pathology likely precedes shedding of 
bacilli into sputum and symptoms. Attempts have been made 
to estimate the duration of sputum positivity before clinical 
presentation, through community surveys which compare 
the prevalence of diagnosed and undiagnosed culture-posi-
tive tuberculosis [9]. The extent of transmission by patients 
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with subclinical tuberculosis is currently unknown. However, 
it is a critically important parameter to understand; modeling 
of transmission during this early stage of tuberculosis indi-
cates that detecting subclinical disease has a large effect on the 
10-year incidence of tuberculosis [10].
Subclinical disease is also important to consider because of 
the potential to lead to the development (and onward transmis-
sion) of drug-resistant bacterial strains following inadvertent 
undertreatment with tuberculosis chemoprophylaxis. In partic-
ular, isoniazid monoresistance may be associated with isoniazid 
preventive therapy [11].
Key events in the pathogenesis of pulmonary tuberculosis are 
necrosis at the site of pneumonia and cavitation [12]. Cavitation 
results in a step up in bacillary load, owing to an increased con-
centration of oxygen which favors bacillary growth, and an 
environment preventing immunological control [13].
Cavity formation is linked to immunocompetence, which 
is notably reduced in human immunodeficiency virus (HIV) 
coinfection, transplant recipients, and elderly individuals 
[14, 15]. The impact of sex, ethnicity, and infecting strain on 
cavitation is less certain. In addition to the impact of general 
immunity, the local environment of granulomata probably 
strongly influences cavity progression [16]. The modulation 
or prevention of cavity formation could have significant 
effects on tuberculosis transmission, through reduced bacte-
rial growth and access to the airways for aerosolization.
Progression of disease once precipitated is unlikely to be 
linear. Spontaneous regression and healing (with subsequent 
fibrosis and calcification) even of symptomatic, cavitary disease 
is long recognized [17]. Similarly, apical fibrocalcific scarring in 
the absence of previous history of disease is frequently observed, 
although with an increased risk of subsequent progression and 
clinical tuberculosis [18].
Extrapulmonary tuberculosis represents a dead end for the 
life cycle of M. tuberculosis, yet determinants of the anatomical 
site of disease are poorly understood. These forms of disease rep-
resent around 15% of all global tuberculosis notifications [19], 
although many cases of extrapulmonary tuberculosis probably 
go unreported because of the difficulty of diagnosis, compared 
with pulmonary disease. Conversely, there may be unrecognized 
pulmonary tuberculosis coexisting with extrapulmonary dis-
ease [20]. Nevertheless, several broad epidemiological variables 
have been associated with a tendency to develop nonpulmonary 
rather than pulmonary tuberculosis, such as female sex, time 
since infection, and, possibly, mycobacterial lineage [20, 21].
The role of HIV coinfection on the infectiousness of patients 
with tuberculosis has been debated [22]. The presence of 
smear-positive sputum or cavitary disease seems to be asso-
ciated with M.  tuberculosis infection in contacts regardless of 
the HIV status of the index case [23]. However, HIV seems to 
reduce infectiousness overall, owing to an association with less 
cavitary disease, lower sputum bacillary loads, a reduced ten-
dency for prolonged illness [24], and, presumably, more-general 
debility in advanced disease, which reduces opportunities for 
social mixing.
Infectiousness ceases with appropriate therapy long before 
pulmonary tuberculosis is cured. A much-reported conclu-
sion by Rouillon et al was that transmission ceases within 2 
weeks after initiating effective antituberculous treatment [25]. 
However, the cited epidemiological studies were limited by 
using as their outcomes the rates of M. tuberculosis infection 
among household contacts of individuals who had been hospi-
talized for treatment. It is likely that most susceptible contacts 
in those homes were exposed and infected before the hospital 
admission of the index case, or even infected outside the house-
hold. The evidence from these data of a 2-week period of infec-
tiousness following initiation of effective treatment is therefore 
limited [26].
Another approach suggested that M. tuberculosis may be via-
ble after 6–7 weeks of treatment, based on the inoculation of 
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Figure 1. Theoretical scheme illustrating some steps and variables important for the transmission of tuberculosis. Abbreviation: HIV, human immunodeficiency virus.
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bacilli from sputum samples into guinea pigs [27]. However, 
experimental studies using natural airborne infection of guinea 
pigs by persons with tuberculosis have suggested that transmis-
sion may stop within 24–48 hours [28]. Limited data in multi-
drug-resistant tuberculosis (MDR-TB) indicate that growth in 
cultures of cough aerosol specimens decreases exponentially 
over 3–21 days after the initiation of effective treatment [29].
The efficacy and availability of treatment are increasing 
problems with the emergence of drug resistance, and they are 
priorities for tuberculosis control. Not only do individuals 
with drug-resistant tuberculosis probably remain infectious 
for longer than those with drug-susceptible disease during 
treatment, treating secondary cases is more complicated and 
costly. The problem might in part be mitigated by a relative 
reduction in the fitness of drug-resistant strains of M. tuber-
culosis. The data on this are conflicting, although a recent 
large prospective study in Peru estimated a reduction in 
transmission to household contacts of about 50% by source 
cases who had MDR-TB as compared to those who had fully 
drug-susceptible disease [30]. This finding may not be uni-
versal to different human populations and MDR M. tubercu-
losis strains [31].
Infectiousness
Source case
When do persons with TB become infectious?  Can those with subclinical TB be infectious?
How important is pulmonary cavitation? 
For how long does TB remain infectious during treatment? How well does sputum culture positivity 
predict infectiousness?
What are the best drugs to rapidly decrease infectiousness in MDR-and XDR-TB? 
Aerosolization
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mechanisms?
Airborne survival
How is the longevity of M. tuberculosis in room air aected by ambient conditions?  
How is this aected by bacterial genotype and phenotype?
Susceptibility
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How important is the inhaled dose of Mtb particles in the pathogenesis of TB in humans?
How important is air pollution in TB transmission?
Infection
Are some individuals truly resistant to TB infection, and if so why?
What is the role of the innate immune response in preventing infection, and how it can it be 
improved in high risk individuals or settings?
How can we develop better models for human TB infection?
Figure 2. Key unanswered questions and research priorities.
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Aerosolization
Although individuals with cavitary disease and a high bacillary 
burden are more likely to release M. tuberculosis into the envi-
ronment, it is clear from epidemiological studies that not all of 
these patients are infectious. This has been confirmed by studies 
using a novel cough aerosol sampling system; only a proportion 
of patients with sputum smear–positive tuberculosis generated 
droplets containing culturable bacilli [32]. Cough aerosol spec-
imens yielding high culture counts were the only predictor of 
new infection among exposed contacts [33]. Bacillary load and 
salivary sputum are predictors of cough aerosol production, but 
there remains considerable unexplained variability in infec-
tiousness among source cases [32].
Droplet particles are released from the respiratory tract 
during all respiratory activities. Relevant variables for droplet 
infectiousness include their number, initial velocity and trajec-
tory, size, and composition [34]. Although there have been very 
few studies involving patients with tuberculosis, in healthy vol-
unteers greater numbers of particles are released during cough-
ing than during tidal breathing or when talking [35]. Singing 
[36] and blowing on wind instruments [37] may also produce 
large numbers of respiratory particles. High shear forces are 
likely to be helpful for releasing bacteria from cavities and areas 
of bronchial obstruction and for overcoming mucus viscosity, 
to allow droplets to tear away from the airway lumen. Coughing 
is associated with more force and higher airflow velocities than 
breathing or talking [38] and is also relevant for the rapid spread 
of airborne bacilli away from the patient in an enclosed space.
Respiratory particles from coughing are probably of higher 
median diameter than those released during talking and tidal 
breathing, in which a larger proportion have a diameter of <1 µm 
[35]. Although influenza virus is found in exhaled breath [39], 
the larger size of M. tuberculosis (>2 µm) probably precludes its 
presence in aerosol particles with a diameter of <1 µm. Because 
viable M. tuberculosis has yet to be demonstrated in breath, the 
apparent increased release of particles during tidal breathing by 
patients with tuberculosis as compared to healthy controls is of 
unclear significance [40].
Although coughing is probably more important than other 
respiratory activities for infectiousness in tuberculosis [34], 
this has been rarely studied. A recent study has confirmed that 
cough frequency is associated with infection in household con-
tacts [41]. Cough frequency seems to be associated with sputum 
bacillary load [42] and is possibly associated with radiographic 
extent of disease [43]. However, other causes of the wide vari-
ation of cough frequency in patients with tuberculosis remain 
largely obscure [34]. Cough strength has been studied even less 
frequently. One study did not find an association of new infec-
tions with cough peak flow rates or observational assessment of 
cough severity [33]. However, another study found subjective 
assessment of cough severity to be associated with more trans-
mission [44].
The nature of airway mucus presumably affects infectious-
ness in at least 2 ways. The rheological properties of secretions, 
including viscosity, elasticity, and cohesivity, predict the poten-
tial for aerosolization [45]. We are not aware of studies of how 
mucus and other components of secretions might protect bacilli 
during aerial transit. Mucus properties vary with disease and 
with other factors, such as smoking [46], although this is another 
topic for which additional research is needed. Furthermore, 
pharmacologically altering the properties of mucus could alter 
the transmissibility of tuberculosis by individuals with diffi-
cult-to-treat (eg, extensively drug-resistant) disease.
Lung capacity, the anatomy of the lower and upper airway, 
and the position of the tongue during coughing probably all 
affect aerosol production, although all appear to have been little 
investigated [34]. In patients with cystic fibrosis, lung function 
is associated with the aerosolization of Pseudomonas aeruginosa 
when coughing [47], but this has not been studied in patients 
with tuberculosis. Behavioral aspects, such as cough hygiene, 
potentially limit the release of infectious aerosols; for exam-
ple, surgical masks worn by patients with tuberculosis have 
been shown to reduce the risk of transmission by >50% [48]. 
Behavioral change clearly depends on conscious awareness of 
coughing, which seems to be variable [43].
Estimates have been made of rates of release of infectious par-
ticles in tuberculosis, mainly using the guinea pig air-sampling 
model [49]. The smallest inhaled dose required for infection, 
presumed (but not definitively proven) to correspond to a single 
bacillus, has been termed a quantum. Release of quanta appears 
highly variable among patients with smear positive disease; 
one particularly infectious individual in one study exceeded 
200 quanta/hour, although the median rate in patients causing 
new infection was 12 quanta/hour (interquartile range, 4.3–39.0 
quanta/hour) [50]. Easier and more-accurate identification of 
the most infectious individuals would be of significant value to 
enable better targeting of infection control measures and con-
tact tracing efforts.
Airborne Survival
Life outside the human host presents a number of potential 
challenges to the survival of M.  tuberculosis. The time during 
which bacilli remain capable of causing infection after release 
into the environment is highly relevant for transmission, yet 
there is a basic lack of knowledge of the longevity of M. tuber-
culosis in open air. Ambient conditions, including ultraviolet 
and ionizing radiation, are relevant, and germicidal irradiation 
is thus used for infection control [51, 52]. Features of the organ-
ism are also important; it has recently been recognized that 
phenotypic changes may occur in M. tuberculosis in association 
with the airborne phase of its life cycle [53].
Investigations of outbreaks of tuberculosis in congregate set-
tings and infection of guinea pigs exposed to air ventilated from 
remote wards housing source patients [28] have highlighted the 
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ability of M.  tuberculosis to remain viable and be transported 
through air in indoor spaces. Novel approaches are required to 
learn more about the aerobiology of M. tuberculosis [49].
SUSCEPTIBILITY
Exposure and Inhalation
Mathematical modeling has informed the variables determining 
the transmission of tuberculosis indoors, especially in demon-
strating the strong effects of poor ventilation and overcrowding 
in increasing exposure of occupants to higher concentrations of 
infectious particles. The effective contact rate is determined by the 
room ventilation rate (calculated as the number of air exchanges 
per hour), room volume, occupation density, and duration of 
exposure [54]. It can be reduced by increasing the room ventila-
tion or volume or reducing the occupation density [54].
The number of air exchanges per hour may be increased 
through natural, mechanical, or mixed methods of ventilation 
[55]. Mechanical ventilation can provide a constant fixed rate 
of air exchange, with control of the airflow direction indepen-
dent of ambient conditions, but it is relatively costly to install, 
requires expertise to maintain, and, in some high-burden set-
tings, is inadequate [56]. Natural ventilation can be achieved by 
opening doors and windows (which can increase the ventila-
tion rate to a value such as 28 air changes/hour), particularly in 
rooms with high ceilings and large windows (which can yield 
an increase of up to 40 air changes/hour) [57]. Determinants of 
natural ventilation include wind speed, window size, and cross 
ventilation [57]. Natural ventilation as compared to mechan-
ical ventilation is cheaper and easier to maintain, and it can 
potentially be used in a large range of settings. However, the 
acceptability and effectiveness of natural ventilation is affected 
by weather and climate conditions, and mechanical ventilation 
might be better suited for providing the optimum design of 
positive pressure ventilation in staff areas and negative pressure 
ventilation in patient areas.
Higher inhaled doses of infectious particles probably more 
likely result in tuberculosis [58]. A determinant of inhaled dose 
is proximity of contact to the source case; individuals sharing 
a bed with people with tuberculosis have the greatest risk of 
becoming infected [59]. The intensity of exposure over time is 
also a surrogate for inhaled dose. Among South African gold 
miners, the estimated annual risk of infection is 20% per year; 
around 89% are infected with M.  tuberculosis after approxi-
mately 20 years in the occupation [60]. Highly exposed health-
care workers in South Africa have a 2–4-fold greater risk of 
M. tuberculosis infection, compared with medical students with 
low exposure [61].
Host variables are relevant for the inhalation of infectious 
particles. Respiratory rate and tidal volume increase the risk of 
infection [54], whereas respirator masks (when used) probably 
help prevent tuberculosis [62]. Barrier host defenses, which 
limit entry of M. tuberculosis into the distal lung, are also clearly 
important and include a functioning respiratory epithelium 
and an effective mucociliary escalator [46, 63]. Smoking is 
an important epidemiological risk factor for tuberculosis and 
probably exerts at least some of its deleterious effect through an 
impact on these basic respiratory defenses [64]. Air pollution 
may also have an important impact [65].
Infection
At present, the mechanisms underlying resistance to M. tuber-
culosis infection in humans remain very poorly understood. 
This is largely due to our inability to accurately discern dispa-
rate outcomes following exposure to M. tuberculosis. The TST 
and IGRAs measure the host response to antigens derived from 
M.  tuberculosis, and their results have been used as a surro-
gate for infection. Epidemiologically, those with evidence of 
exposure to mycobacterial antigens are at much higher risk of 
progression to tuberculosis [66], although only a minority of 
individuals with positive test results develop disease. Continued 
negative results of TST or IGRAs following exposure to an 
infectious source case could be interpreted as indicating resis-
tance to infection or a lack of true exposure. A major limitation 
in this regard has been the absence of animal models that reflect 
resistance, although studies performed in both cattle and rab-
bits have been promising [67, 68]. Another limitation has been 
tools that reflect true exposure, as many sources cases who have 
traditionally been thought to be infectious by virtue of having 
positive results of a sputum smear for acid-fast bacilli may not 
produce infectious aerosol [32].
Conceptually, resistance could be considered to reflect early 
clearance, exposure without evidence of adaptive immunity, or 
transient infection, as might be reflected in either reversion of 
TST or IGRA findings. Supporting the concept of early clear-
ance are studies that have demonstrated the heritability of the 
TST response [69], as well as anecdotal reports of individuals 
who are repeatedly exposed to M. tuberculosis but continue to 
have negative TST or IGRA results. TST and IGRA test result 
reversions have been widely observed [70], and it is intriguing 
to note that, in a guinea pig model, reversion was associated 
with mycobacterial clearance following infection [71].
The well-known epidemiological correlates of vulnerability 
to tuberculosis are generally those promoting the development 
of disease once exposed to M.  tuberculosis. In contrast, cor-
relates of resistance to tuberculosis remain poorly understood. 
This is especially relevant to vaccine design, as the ideal vaccine 
would be one that prevents infection, rather than one that just 
diminishes the bacterial burden. In this regard, much of the 
vaccine modeling, either in mice, guinea pigs, or nonhuman 
primates, has not demonstrated prevention of infection and 
therefore does not yet provide evidence for a potential effect on 
tuberculosis transmission. Here, our current understanding of 
the mechanisms by which M. tuberculosis is controlled may not 
fully reflect the natural history that is seen in humans. In partic-
ular, the current paradigm of immune control of M. tuberculosis 
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has centered on the granuloma and on the interaction of T cells 
with the infected cell. Specifically, it is widely believed that 
proinflammatory cytokines, such as interferon γ and tumor 
necrosis factor, can control intracellular growth of M. tubercu-
losis within macrophages through the production of NO and 
H2O2. However, recent evidence suggests that this model is 
incomplete. One challenge is that the macrophage is considered 
both the host and controller of M. tuberculosis [72].
Recent evidence, though, suggests that macrophages play a 
key role in the dissemination of M. tuberculosis [67, 73]. Further 
challenging this paradigm is recent work on the role of induc-
ible NO synthase (iNOS) in the control of M.  tuberculosis. 
Specifically, iNOS-deficient mice are vulnerable to infection with 
M. tuberculosis, supporting the model of NO-dependent control 
of M.  tuberculosis replication [74]. However, this concept has 
been recently challenged by careful experiments in which myco-
bacterial growth can be distinguished from inflammation. Here, 
iNOS appears to regulate neutrophil-driven inflammation inde-
pendently of the control of mycobacterial growth [75].
These data, then, leave open the question of how the immune 
system might contain infection with M.  tuberculosis. One 
surprising finding is that cattle engineered to have enhanced 
macrophage expression of the TALE nickase are resistant to 
natural transmission of M. tuberculosis [68]. However, it is not 
clear how this might be translated into an improved vaccine. 
To address this, there are at least 3 possibilities. The first would 
be to improve macrophage function through the so-called 
training of stable epigenetic changes. Indeed, it has been pro-
posed that this might be one way in which BCG vaccine can 
confer protection against nonmycobacterial diseases [76]. The 
second would be to develop a vaccine that elicits neutralizing, 
lung-resident antibodies. While available animal models have 
not supported this approach, none of them replicates preven-
tion of infection. As a result, this concept is largely untested, 
and the role of antibodies in protection against tuberculosis 
remains controversial [77], although some recent data are very 
interesting in this respect [78]. The third possibility would be 
a vaccine that directs improved recognition of the infected cell 
in the lung. Because T cells can discern intracellular infection, 
this is an attractive possibility. In this regard, mucosal-associ-
ated invariant T (MAIT) cells are an innate-like T-cell subset 
prevalent in humans and enriched in the airway. Human MAIT 
cells have been defined by the expression of the semiinvari-
ant T-cell receptor α chain TRAV1-2/TRAJ12/20/33 and their 
restriction by the nonpolymorphic major histocompatibility 
complex (MHC) class  I–like molecule MHC-related protein 
1.  MAIT cells recognize M.  tuberculosis and are activated by 
small organic molecules derived from the riboflavin biosyn-
thesis pathway of bacteria and fungi [79]. Alternatively, aerosol 
delivery of conventional vaccines has the potential to generate a 
population of T cells capable of early recognition of M. tubercu-
losis–infected cells [80].
Ultimately, in considering vaccines or host-directed strat-
egies to prevent infection with M.  tuberculosis, modeling will 
be needed to evaluate novel concepts and approaches. These 
could be either improved animal models that reflect prevention 
of infection or human challenge models, as has been done for 
malaria. Because the mouse model continues to be a necessary 
first step in vaccine development, development of these models 
should be a high priority, possibly through the use of alternate 
mouse strains or in the generation of ultra-low-dose challenge 
models.
OTHER CONSIDERATIONS
Central to the transmission of tuberculosis is M. tuberculosis, an 
organism that has evolved with its human host over millennia 
[81]. As already discussed in relation to drug-resistant strains, 
organism phenotype and lineage have been noted to be a deter-
minant of virulence and transmissibility. The mechanisms 
through which this may arise are potentially numerous, pos-
sibly affecting every stage of transmission and disease in ways 
that are yet to be elucidated [44, 82].
Although M.  tuberculosis is unique in its microbiology 
and immunopathology, some insight can be gained into the 
processes of respiratory pathogen transmission from study-
ing viruses. Common features exist, both conceptual and 
mechanistic.
Respiratory viruses are generally thought to be transmit-
ted by direct contact and large-droplet transmission, although 
there is controversy about the role of airborne transmission [83]. 
Mucosal immunity is likely to have direct impact on transmis-
sion by blocking or reducing viral shedding. Although serum 
neutralizing antibodies are the most widely studied and best 
understood correlates of protection, it is clear that systemic anti-
body levels often correlate poorly with susceptibility to infection 
or disease and that better correlates need to be identified, as with 
M. tuberculosis [84, 85]. The role of antibody in the susceptibility 
to M. tuberculosis and modulation of disease is controversial, and 
further investigation of mucosal responses is warranted [77].
The common anatomical site of M.  tuberculosis and respi-
ratory viral infections therefore leads to parallel dilemmas 
and potential approaches for further study. Recent studies of 
 vaccine-induced and mucosal immunity [86] and of immuno-
pathology in the context of experimental human influenza virus 
[87] and respiratory syncytial virus infections [88, 89], partic-
ularly in the lower airway, have broadened our understanding 
of the protective responses required to prevent infection, dis-
ease, and onward transmission. Similar developments in the 
M. tuberculosis field may therefore yield similar benefits.
Conversely, studies of tuberculosis transmission may also 
inform the epidemiology of other bacterial diseases. The cough 
aerosol sampling system first developed to collect infectious aero-
sols containing M. tuberculosis has been used to demonstrate the 
generation and transport of viable aerosols of P. aeruginosa and 
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other gram-negative bacteria from persons with cystic fibrosis 
[47, 90]. These data suggest that understanding the modes and 
underlying mechanisms of various pathogens may have inter-
disciplinary benefit and could help better inform the scientific 
basis of infection control and public health policies.
CONCLUSION
The transmission of tuberculosis is highly complex. Close con-
sideration of the steps M.  tuberculosis must take to leave one 
infectious individual and ultimately initiate infection and dis-
ease in a susceptible new host, as well as the many relevant 
variables that influence these steps, should lead to improved 
understanding of how transmission occurs and to increased 
chances for elimination of the disease.
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